R&D Pipeline
R&D Pipeline 정보
| Indication |
Discovery |
Preclinical |
Phase 1 |
Phase 2 |
Phase 3 |
| Burfiralimab(IgG4) |
|
|
|
|
|
| Chronic Hepatitis B |
|
|
|
|
|
| Influenza-Induced Pneumonia |
|
|
|
|
|
| Rheumatoid Arthritis |
|
|
|
|
|
| IM-02(IgG1) |
|
|
|
|
|
| Virus-Induced Cancer |
|
|
|
|
|
| Small molecule * |
|
|
|
|
|
| Viral Pneumonia(COVID-19) |
|
|
|
|
|
| Oncology(PDAC) |
|
|
|
|
|
| cGvHD |
|
|
|
|
|
| IMV-01(Dengue Vaccine) |
|
|
|
|
|
* Collaboration with DGMIF
[The Current Progress of COVID-19]
- 1)According to Regulation on Safety of Medicinal product, etc. Clause 28, article 3 [Treatment purpose usage approval], SNUH physician's application which allows IP to be administered to individual patient has been approved on 21Feb2020.
- 2)ImmuneMed Inc. supplied investigational product, hzVSF-v13 to the site on 24Feb2020.
- 3)It is expected to have a significant therapeutic effect with the administration of investigational product in patients with severe new coronavirus
(COVID-19) pneumonia.